Solid cannabinoid composition for parenteral use
Patent Information
- Application Number
- HK62026126887
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-12
- Filing Date
- 2026-07-30
- Publication Date
- 2026-09-11
Abstract
Description
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number WO 2024 / 235489 A1 WIPO PCT21 November 2024 (21.11.2024) (51) International Patent Classification: A61K 31 / 00 (2006.01) A61K 9 / 16 (2006.01) A61K 9 / 19 (2006.01) A61K 9 / 00 (2006.01) LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: Published: PCT / EP2024 / 051266 with international search report (Art. 21(3)) (22) International Filing Date: 19 January 2024 (19.01.2024) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 23173362.7 23203283.9 15 May 2023 (15.05.2023) EP 12 October 2023 (12.10.2023) EP (71) Applicant: BENDER ANALYTICAL HOLDING B.V. [NL / NL]; Oude Holleweg 6, 6572 AB Berg en Dal (NL). (72) Inventors: MICHORIUS, Johannes Albertus; Oude Holleweg 6, 6572 AB Berg en Dal (NL). BENDER, Jo- hannes Caspar Mathias Elizabeth; Oude Holleweg 6, 6572 AB Berg en Dal (NL). (74) Agent: NEDERLANDSCH OCTROOIBUREAU; P.O. Box 29720, 2502 LS The Hague (NL). (81) (84) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AМ, AO, AТ, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM. DO, DZ, EC, EE, EG, ES, FI, GB, GD. GE, GH, GM, GT. HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY. MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH. TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS. ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, (54) Title: SOLID CANNABINOID COMPOSITION FOR PARENTERAL USE (57) Abstract: A solid cannabinoid composition comprising: (i) 0.3-10 wt.% of one or more cannabinoids; (ii) 4-69 wt.% of one or more non-ionic surfactants with an HLB value of 10-25; and (iii) at least 20 wt.% of one or more carbohydrates selected from mannitol, sucrose, trehalose and stachyose;⚫ (iv) 0-5 wt.% water, wherein the combination of the one or more non-ionic surfactants and the one or more carbohydrates constitutes at least 70 wt.% of the composition. A sterile aqueous liquid for use in medical treatment, said liquid comprising: (a) 0.1 - 10 mg / mL of one or more cannabinoids; (b) one or more non-ionic surfactants with an HLB value of 10-25; (c) one or more carbohydrates selected from mannitol, sucrose, trehalose and stachyose; and (d) at least 85 wt.% water; wherein the one or more non-ionic surfactants and the one or more cannabinoids are present in the sterile aqueous liquid in a weight ratio of 3:1 to 30:1 and wherein the one or more carbohydrates and the one or more cannabinoids are present in the sterile aqueous liquid in a weight ratio of 3:1 to 300:1. W O 2 0 2 4 / 2 3 5 4 8 9 A 1 WO 2024 / 235489 PCT / EP2024 / 051266 SOLID CANNABINOID COMPOSITION FOR PARENTERAL USE Field of the invention 5 10 15 This invention relates to a solid cannabinoid composition for parenteral use. The solid pharmaceutical composition of the present invention can suitably be combined with a sterile aqueous liquid to produce a parenterally administrable liquid. The solid cannabinoid compositions of the present invention are very stable and dissolve very rapidly in aqueous liquids, thus enabling quick preparation of parenterally administrable liquid. The present cannabinoid composition can suitably be used in the treatment of neonates at risk of seizures and brain injury, especially in the treatment of Hypoxic-Ischemic Encephalopathy (HIE). Background of the invention 20 Cannabinoids are highly hydrophobic substances with very poor water solubility. Cannabidiol, for instance, has a water solubility of 0.0627 µg / mL. Tetrahydrocannabinol (THC), another cannabinoid with various therapeutic uses, has a water solubility of 0.0028 mg / mL (23 °C). Thus, in order to prepare a parenterally administrable aqueous liquid containing sufficient cannabinoid to be therapeutically effective, solubility of cannabinoid 25 needs to be enhanced. 30 Cannabinoids suffer from limited stability, notably as a result of oxidation, especially when applied in water-containing formulations. HIE is caused by a lack of oxygen and / or blood flow getting to the neonate from the placenta. There are currently no approved drugs or medicinal therapies for HIE and the standard of care is therapeutic hypothermia, which benefits only a select group of new- borns. Each year, more than two million neonates die or evolve to permanent invalidating sequelae worldwide because of HIE. 35 1 WO 2024 / 235489 PCT / EP2024 / 051266 5 10 Preclinical studies offer solid evidence of the neuroprotective effects of Cannabidiol (CBD). Such effects are observable in the short and long term as demonstrated by functional, neuroimaging, histologic and biochemical studies, and are related to the modulation of excitotoxicity, inflammation and oxidative stress - the major components of HIBI pathophysiology. CBD protects neuronal and glial cells, with a remarkable effect on preserving normal myelinogenesis. Therefore CBD is a valuable tool for HIE management since it is safe and effective. It is administered by the parenteral route a posteriori with a broad therapeutic time window. WO 2018 / 002636 describes an aqueous parenteral cannabinoid containing formulation comprising: (i) a cannabinoid; (ii) an isotonic agent; (iii) a surfactant; and 15 (iv) one or more stability enhancers. WO 2022 / 174352 concerns a single-phase, injectable cannabinoid formulation for parenteral administration. The formulation contains at least one cannabinoid fully dissolved in a co- solvent system. The co-solvent system contains (i) an effective amount of at least one 20 triglyceride; (ii) an effective amount of at least one C6 to C22 fatty acid; (iii) from about 1 to about 3% w / v of at least one phosphatidylglycerol and / or salt thereof; and (iv) (optionally) an effective amount of at least one antioxidant (or preservative) to improve shelf-life. The formulations are free of water and ethanol. 25 30 35 WO 2022 / 017911 concerns the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes related to brain injury. The described CBD preparation comprises greater than 95% (w / w) CBD and between 0.01 and 0.15% (w / w) tetrahydrocannabinol (THC). An injectable form is not mentioned. US 2019 / 015383 describes a water soluble cannabinoid composition comprising: a purified cannabinoid mixture; at least one carrier oil; and at least one water soluble agent chosen from a complex carbohydrate, a polyol, a polysaccharide, an oligosaccharide, or a combination thereof; 2 WO 2024 / 235489 PCT / EP2024 / 051266 5 10 wherein the composition is soluble in water at a temperature less than or equal to about 20° C.; and wherein the composition is in the form of agglomerated particles. US 2023 / 030491 describes a liquid emulsifying formulation comprising: i) one or more cannabinoids, and / or a cannabinoid extract; ii) one or more surfactants; and iii) one or more oils, wherein the weight ratio of the one or more surfactants to the one or more cannabinoids, and / or the cannabinoid extract is from about 1:1 to about 20:1 and the weight ratio of the one or more oils to the one or more cannabinoids, and / or the cannabinoid extract is from about 1:1 to about 10:1. 15 20 25 30 35 Summary of the invention The inventors have developed a solid cannabinoid composition that is highly stable and that can suitably be used to prepare a parenterally administrable aqueous liquid within a short period of time, simply by mixing the solid composition with aqueous liquid, such as a sterile isotonic aqueous liquid. The solid cannabinoid composition according to the present invention comprises: (i) 0.3-10 wt.% of one or more cannabinoids; (ii) 4-69 wt.% of one or more non-ionic surfactants with an HLB value of at least 10. preferably of 10-25; (iii) at least 20 wt.% of one or more carbohydrates selected from mannitol, sucrose, trehalose and stachyose; (iv) 0-5 wt.% water; wherein the combination of the one or more non-ionic surfactants and the one or more carbohydrates constitutes at least 70 wt.% of the composition. The solid cannabinoid composition of the present invention can suitably be prepared by freeze drying an aqueous liquid comprising the one or more cannabinoids, one or more non- ionic surfactants having an HLB of 10 to 25 and one or more carbohydrates selected from mannitol, sucrose, trehalose and stachyose in appropriate concentrations. The solid cannabinoid composition so obtained is highly porous and comprises a carbohydrate matrix that is largely amorphous and in a glassy state. Although the inventors do not wish to be bound by theory, it is believed that this combination of features and the presence of a non- 3 一種固體大麻素組合物,其包含:• (i) 0.3-10 wt.%的一種或多種大麻 素;• (ii) 4-69 wt.%的一種或多種 HLB 值為 10-25 的非離子表面活性劑;以及• (iii) 至少 20 wt.%的一種或多種選自甘露醇、蔗糖、海藻糖和水蘇糖的碳水化合物;• (iv) 0-5 wt.%的水;其中所述一種或多種非離子表面活性劑和所述一種或多種碳水化合物 的組合占所述組合物的至少 70 wt.%。一種用於醫學治療的無菌水性液體,所述液體包 含:(a) 0.1-10 mg / mL 的一種或多種大麻素;(b) 一種或多種 HLB 值為 10-25 的非離子 表面活性劑;(c) 一種或多種選自甘露醇、蔗糖、海藻糖和水蘇糖的碳水化合物;以及 (d) 至少 85 wt.%的水;其中所述一種或多種非離子表面活性劑和所述一種或多種大麻 素以 3:1 至 30:1 的重量比存在於所述無菌水性液體中,並且其中所述一種或多種碳水 化合物和所述一種或多種大麻素以 3:1 至 300:1 的重量比存在於所述無菌水性液體中。 摘要
Claims
CLAIMS1. A solid cannabinoid composition comprising:(i) 0.3-10 wt.% of one or more cannabinoids;(ii) 4-69 wt.% of one or more non-ionic surfactants with an HLB value of 10-25;(iii) at least 20 wt.% of one or more carbohydrates selected from mannitol, sucrose, trehalose and stachyose;(iv) 0-5 wt.% water; wherein the combination of the one or more non-ionic surfactants and the one or more carbohydrates constitutes at least 70 wt.% of the composition.
2. The solid cannabinoid composition according to claim 1 , wherein the solid composition has a density of 10 to 200 mg / mL.
3. The solid cannabinoid composition according to claim 1 or 2, wherein the one or more cannabinoids are selected from Tetrahydrocannabinol, De / ta-9-tetrahydrocannabinol, De / ta-8-Tetrahydrocannabinol, Cannabidiol, Cannabinol, 11-hydroxy- tetrahydrocannabinol, 11-hydroxy-De / ta-9-tetrahydrocannabinol, Delta-11- Tetrahydrocannabinol and Tetrahydrocannabivarin, Levonantradol and Nabilone, preferably selected from Tetrahydrocannabinol, De / ta-9-tetrahydrocannabinol, Delta-8- Tetrahydrocannabinol, Cannabidiol and Cannabinol, most preferably selected from Cannabidiol and Tetrahydrocannabinol.
4. The solid cannabinoid composition according to claim 3, wherein the cannabinoid is selected from cannabidiol, tetrahydrocannabinol and combinations thereof.
5. The solid cannabinoid composition according to any one of the preceding claims, wherein the composition contains at least 4 wt.% of non-ionic surfactants with an HLB value in the range of 11 to 18, preferably in the range of 12 to 16.
6. The solid cannabinoid composition according to any one of the preceding claims, wherein the one or more non-ionic surfactants are fatty acid esters of polyethylene glycol.
7. The solid cannabinoid composition according to claim 6, wherein the fatty acid esters of polyethylene glycol are selected from esters of glycerol polyethylene glycol and C12 - C20 hydroxy fatty acids, esters of polyethylene glycol and C12 - C20 hydroxy fatty acids, esters of polyethylene glycol sorbitol and C12-C20 fatty acids and combinations thereof.
8. The solid cannabinoid composition according to any one of the preceding claims, wherein the one or more carbohydrates are selected from mannitol, sucrose, trehalose and stachyose.
9. The solid cannabinoid composition according to claim 8, wherein the one or more carbohydrates is mannitol.
10. The solid cannabinoid composition according to any one of the preceding claims, wherein the solid cannabinoid composition contains 0-1 wt.% triglycerides.
11. The solid cannabinoid composition according to claim 10, wherein the solid cannabinoid composition contains 0-1 wt.% of oil, said oil being selected from fatty acids, monoglycerides, diglycerides, triglycerides, propylene glycol mono esters, propylene glycol diesters and combinations thereof.
12. The solid cannabinoid composition according to any one of the preceding claims, wherein the solid cannabinoid composition contains triglycerides and the one or more cannabinoids in a weight ratio of triglycerides : one or more cannabinoids that is in the range of 0 to 1.
13. The solid cannabinoid composition according to claim 12, wherein the solid cannabinoid composition contains oil and the one or more cannabinoids in a weight ratio of oil : one or more cannabinoids that is in the range of 0 to 1 , said oil being selected from fatty acids, monoglycerides, diglycerides, triglycerides, propylene glycol mono esters, propylene glycol diesters and combinations thereof.
14. The solid cannabinoid composition according to any one of the preceding claims, wherein the composition, when dispersed in distilled water having a temperature of 37°C in a concentration of 10 to 200 mg / mL, yields an aqueous liquid having an osmolarity in the range of 100 to 800 mOsm / L.
15. A method of preparing the solid cannabinoid composition according to any one of claims 1 - 14, said method comprising freeze drying an aqueous liquid comprising: a. 0.1-10 mg / mL of one or more cannabinoids; b. one or more non-ionic surfactants with an HLB value of 10-25; c. one or more carbohydrates selected from mannitol, sucrose, trehalose and stachyose; andd. at least 85 wt.% water; wherein the one or more non-ionic surfactants and the one or more cannabinoids are present in the aqueous liquid in a weight ratio of 3:1 to 30:1 and wherein the one or more carbohydrates and the one or more cannabinoids are present in the aqueous liquid in a weight ratio of 3: 1 to 300: 1 .
16. A vial or a syringe comprising the solid cannabinoid composition according to any one of claims 1-14 in an amount that provides 0.2-100 mg cannabinoid.
17. A sterile aqueous liquid for use in medical treatment, said liquid comprising:(a) 0.1 - 10 mg / mL of one or more cannabinoids;(b) one or more non-ionic surfactants with an HLB value of 10-25;(c) one or more carbohydrates selected from mannitol, sucrose, trehalose and stachyose; and(d) at least 85 wt.% water; wherein the one or more non-ionic surfactants and the one or more cannabinoids are present in the sterile aqueous liquid in a weight ratio of 3:1 to 30:1 and wherein the one or more carbohydrates and the one or more cannabinoids are present in the sterile aqueous liquid in a weight ratio of 3: 1 to 300: 1 .
18. The sterile aqueous liquid for use in medical treatment according to claim 17, wherein the one or more cannabinoids are selected from Tetrahydrocannabinol, Delta-9- tetrahydrocannabinol, De / ta-8-Tetrahydrocannabinol, Cannabidiol, Cannabinol, 11- hydroxy-tetrahydrocannabinol, 11-hydroxy-De / ta-9-tetrahydrocannabinol, Delta-11- Tetrahydrocannabinol and Tetrahydrocannabivarin, Levonantradol and Nabilone, preferably selected from Tetrahydrocannabinol, De / ta-9-tetrahydrocannabinol, Delta-8- Tetrahydrocannabinol, Cannabidiol and Cannabinol, most preferably selected from Cannabidiol and Tetrahydrocannabinol.
19. The sterile aqueous liquid for use in medical treatment according to claim 17 or 18, wherein the one or more non-ionic surfactants have an HLB value in the range of 11 to 18, preferably in the range of 12 to 16.
20. The sterile aqueous liquid for use in medical treatment according to claim according to any one of claims 17-19, wherein the one or more non-ionic surfactants are fatty acid esters of polyethylene glycol.21 . The sterile aqueous liquid for use in medical treatment according to any one of claims 17-20, wherein the one or more non-ionic surfactants are selected from esters of glycerol polyethylene glycol and C12 - C20 hydroxy fatty acids, esters polyethylene glycol and C12 - C20 hydroxy fatty acids, esters of polyethylene glycol sorbitol and C12-C20 fatty acids and combinations thereof.
22. The sterile aqueous liquid for use in medical treatment according to any one of claims I -21 , wherein the one or more carbohydrates are selected from mannitol, sucrose, trehalose and stachyose.
23. The sterile aqueous liquid for use in medical treatment according to claim 22, wherein the one or more carbohydrates are mannitol.
24. The sterile aqueous liquid for use in medical treatment according to any one of claims 17-23, wherein the sterile aqueous liquid contains 0-10 mg / L triglycerides.
25. The sterile aqueous liquid for use in medical treatment according to claim 24, wherein the sterile aqueous liquid contains 0-10 mg / L of oil, said oil being selected from fatty acids, monoglycerides, diglycerides, triglycerides, propylene glycol mono esters, propylene glycol diesters and combinations thereof.
26. The sterile aqueous liquid for use in medical treatment according to any one of claims 17-25, wherein the sterile aqueous liquid contains triglycerides and the one or more cannabinoids in a weight ratio of triglycerides : one or more cannabinoids that is in the range of 0 to 1.
27. The sterile aqueous liquid for use in medical treatment according to claim 26, wherein the sterile aqueous liquid contains oil and the one or more cannabinoids in a weight ratio of oil: one or more cannabinoids that is in the range of 0 to 1 , said oil being selected from fatty acids, monoglycerides, diglycerides, triglycerides, propylene glycol mono esters, propylene glycol diesters and combinations thereof.
28. The sterile aqueous liquid for use in medical treatment according to any one of claims IT- 27, wherein the sterile aqueous liquid is prepared by combining a solid cannabinoid composition according to any one of claims 1-14 with a sterile liquid containing at least 90 wt.% water.
9. The sterile aqueous liquid for use in medical treatment according to any one of claims 17-28, wherein the medical treatment comprises parenteral administration, preferably intravenous administration of the sterile aqueous liquid.
